Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
暂无分享,去创建一个
E. Giné | M. Czuczman | J. Winter | B. Coiffier | A. Rohatiner | J. Sierra | C. Gisselbrecht | M. Schuler | A. Advani | J. Boni | G. Verhoef | I. Schmidt-Wolf | M. Dreyling | L. Fayad | Mitchell R. Smith | E. Vandendries | J. Foran | S. Nasta | N. Ketterer | M. Shapiro
[1] E. Giné,et al. Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study , 2008 .
[2] N. Damle,et al. Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma , 2006, Clinical Cancer Research.
[3] N. Damle,et al. Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma , 2004, Clinical Cancer Research.
[4] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[5] Boris Gorovits,et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.
[6] Donald E. Mager,et al. General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[7] S. Langermann,et al. Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.
[8] G. McDonald,et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.
[9] Irwin Hollander,et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. , 2002, Bioconjugate chemistry.
[10] I. T. Ten Berge,et al. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. , 2002, The Journal of pharmacology and experimental therapeutics.
[11] M. Berger,et al. Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse , 2001, Journal of clinical pharmacology.
[12] A. Heider,et al. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas , 2001, Anti-cancer drugs.
[13] J. Thorson,et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.
[14] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Raimund J. Ober,et al. Increasing the serum persistence of an IgG fragment by random mutagenesis , 1997, Nature Biotechnology.
[19] R. Wallace,et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. , 1993, Cancer research.
[20] M. Siegel,et al. Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I, .gamma.1I, and .delta.1I , 1992 .
[21] K. Foon,et al. Immune markers in hematologic malignancies. , 1991, Critical reviews in oncology/hematology.
[22] G. Ellestad,et al. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. , 1988, Science.
[23] T. Waldmann,et al. Metabolism of immunoglobulins. , 1969, Progress in allergy.
[24] F. W. R. BRAMBELL,et al. A Theoretical Model of γ-Globulin Catabolism , 1964, Nature.